Cochrane Abstracts
Best first‐line therapy for people with advanced non‐small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Best First‐line Therapy for People With Advanced Non‐small Cell Lung Cancer, Performance Status 2 Without a Targetable Mutation or With an Unknown Mutation Status." Cochrane Abstracts, John Wiley & Sons, Inc, 2024. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/440508/all/Best_first‐line_therapy_for_people_with_advanced_non‐small_cell_lung_cancer_performance_status_2_without_a_targetable_mutation_or_with_an_unknown_mutation_status.
Best first‐line therapy for people with advanced non‐small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status. Cochrane Abstracts. John Wiley & Sons, Inc; 2024. https://evidence.unboundmedicine.com/evidence/view/Cochrane/440508/all/Best_first‐line_therapy_for_people_with_advanced_non‐small_cell_lung_cancer_performance_status_2_without_a_targetable_mutation_or_with_an_unknown_mutation_status. Accessed December 13, 2024.
Best first‐line therapy for people with advanced non‐small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status. (2024). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/440508/all/Best_first‐line_therapy_for_people_with_advanced_non‐small_cell_lung_cancer_performance_status_2_without_a_targetable_mutation_or_with_an_unknown_mutation_status
Best First‐line Therapy for People With Advanced Non‐small Cell Lung Cancer, Performance Status 2 Without a Targetable Mutation or With an Unknown Mutation Status [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2024. [cited 2024 December 13]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/440508/all/Best_first‐line_therapy_for_people_with_advanced_non‐small_cell_lung_cancer_performance_status_2_without_a_targetable_mutation_or_with_an_unknown_mutation_status.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Best first‐line therapy for people with advanced non‐small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status
ID - 440508
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/440508/all/Best_first‐line_therapy_for_people_with_advanced_non‐small_cell_lung_cancer_performance_status_2_without_a_targetable_mutation_or_with_an_unknown_mutation_status
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
